retatrutide clinical trials retatrutide mechanism First phase 3 data, a Triumph of Science! Retatrutide: Complete Triple Agonist Research

Cravings are often linked to physiological or psychological cues

Changes are slow and steady

There are are 4 planned TRIUMPH trials investigating retatrutide's efficacy in treating obesity and its complications: #type2diabetes #cardiovascular disease #osteoarthritis NEW Data drop at #ADA2023: Retatrutide, a triple agonist (GLP1, GIP, glucagon) lost an incredible 24.2% of their body weight, which amounts to 58 lbs

"And the happy accident involved a rat called the Brattleboro rat." Brattleboro rats are laboratory rodents with a genetic mutation that makes them thirsty nearly all the time

Giving exogenous GLP-1 analogues or increasing endogenous GLP-1 levels can enhance the signaling of GLP-1R, and the activation of GLP-1R can effectively inhibit glucagon secretion in human body